Valeria Antsupova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valeria Antsupova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Magnus Arpi
Department of Clinical Microbiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
2 shared publicationsJens Otto Jarløv
Department of Clinical Microbiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
1 shared publication- Jette Nygaard Jensen
Department of Clinical Microbiology, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark
1 shared publication - Jonas Bredtoft Boel
Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark
1 shared publication - Nis Nørgaard
Department of Urology, Herlev Gentofte University Hospital, Herlev, Denmark
1 shared publication Rasmus Bisbjerg
Department of Urology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
1 shared publication
Latest Publications
- Open Access
- 26 November 2014
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (3) , 957-958
Antibiotic prophylaxis for transrectal prostate biopsy--a new strategy--authors' response
Synergistic effect. This strategy eliminated fluoroquinolones from the therapeutic regimen and differed significantly from the studies recruited in our meta-analysis, which usually added one aminoglycoside or cephalosporin (usually one intramuscular or intravenous dose) to the basic use of quinolone or other antibiotic treatments. Augmented prophylaxis appears to have a bright future in reducing post-TRPB UTI. However, it remains unclear as to whether the fluoroquinolone-based prophylactic strategy should be completely abandoned and which augmented prophylaxis strategy is most suitable.
- 26 November 2014
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (3) , 957-958
Open AccessAntibiotic prophylaxis for transrectal prostate biopsy--a new strategy--authors' response
Synergistic effect. This strategy eliminated fluoroquinolones from the therapeutic regimen and differed significantly from the studies recruited in our meta-analysis, which usually added one aminoglycoside or cephalosporin (usually one intramuscular or intravenous dose) to the basic use of quinolone or other antibiotic treatments. Augmented prophylaxis appears to have a bright future in reducing post-TRPB UTI. However, it remains unclear as to whether the fluoroquinolone-based prophylactic strategy should be completely abandoned and which augmented prophylaxis strategy is most suitable.
- Open Access
- 11 August 2014
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (12) , 3372-3378
Antibiotic prophylaxis for transrectal prostate biopsy--a new strategy
Fluoroquinolones are extensively used as prophylaxis for transrectal ultrasound-guided biopsy of the prostate (TRUBP). Emerging fluoroquinolone resistance and selection of multiresistant organisms warrant new prophylactic strategies. Pivmecillinam and amoxicillin/clavulanic acid have mutual synergistic activity and the combination of these agents has a broad coverage of the majority of microorganisms causing infectious complications after TRUBP and may be a valuable future prophylactic regimen. This was a retrospective cohort study of 2624 men that underwent TRUBP at a Danish university hospital. The patients were divided into three groups. Group 1 (n = 1220) received ciprofloxacin before TRUBP, Group 2 (n = 240) received a combination of pivmecillinam and amoxicillin/clavulanic acid before TRUBP and Group 3 (n = 1161) received an extended prophylaxis with pivmecillinam and amoxicillin/clavulanic acid before and for 2 days after TRUBP. One hundred and ten out of 148 (74.3%) post-TRUBP infections were caused by Escherichia coli, Klebsiella pneumoniae or Enterococcus faecalis. Group 3 with the extended prophylaxis with pivmecillinam and amoxicillin/clavulanic acid had a significantly lower rate of bacteraemia (0.9%) as compared with Group 1 (1.8%) and Group 2 (3.7%). A significant fall in the proportion of ESBL-producing Enterobacteriaceae was observed from the period when ciprofloxacin was used as prophylaxis (8.1%) compared with the subsequent period when pivmecillinam and amoxicillin/clavulanic acid was used (5.9%). The combination of pivmecillinam and amoxicillin/clavulanic acid is an attractive prophylaxis for TRUBP from a clinical, bacteriological and ecological point of view as compared with ciprofloxacin.
- 11 August 2014
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (12) , 3372-3378
Open AccessAntibiotic prophylaxis for transrectal prostate biopsy--a new strategy
Fluoroquinolones are extensively used as prophylaxis for transrectal ultrasound-guided biopsy of the prostate (TRUBP). Emerging fluoroquinolone resistance and selection of multiresistant organisms warrant new prophylactic strategies. Pivmecillinam and amoxicillin/clavulanic acid have mutual synergistic activity and the combination of these agents has a broad coverage of the majority of microorganisms causing infectious complications after TRUBP and may be a valuable future prophylactic regimen. This was a retrospective cohort study of 2624 men that underwent TRUBP at a Danish university hospital. The patients were divided into three groups. Group 1 (n = 1220) received ciprofloxacin before TRUBP, Group 2 (n = 240) received a combination of pivmecillinam and amoxicillin/clavulanic acid before TRUBP and Group 3 (n = 1161) received an extended prophylaxis with pivmecillinam and amoxicillin/clavulanic acid before and for 2 days after TRUBP. One hundred and ten out of 148 (74.3%) post-TRUBP infections were caused by Escherichia coli, Klebsiella pneumoniae or Enterococcus faecalis. Group 3 with the extended prophylaxis with pivmecillinam and amoxicillin/clavulanic acid had a significantly lower rate of bacteraemia (0.9%) as compared with Group 1 (1.8%) and Group 2 (3.7%). A significant fall in the proportion of ESBL-producing Enterobacteriaceae was observed from the period when ciprofloxacin was used as prophylaxis (8.1%) compared with the subsequent period when pivmecillinam and amoxicillin/clavulanic acid was used (5.9%). The combination of pivmecillinam and amoxicillin/clavulanic acid is an attractive prophylaxis for TRUBP from a clinical, bacteriological and ecological point of view as compared with ciprofloxacin.